시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
경련성 발성장애 치료 시장 보고서(2025년)
Spasmodic Dysphonia Treatment Global Market Report 2025
상품코드 : 1825909
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,661,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,629,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,596,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

경련성 발성장애 치료 시장 규모는 향후 몇 년 동안 안정적인 성장이 예상됩니다. 2029년에는 CAGR 4.3%로 170억 5,000만 달러로 성장할 것입니다. 예측 기간의 성장은 신경 질환에 대한 인식 증가, 비수술적 치료에 대한 수요 증가, 발성 장애 유병률 증가, 맞춤형 의료 접근법 채택 증가, 원격의료 및 원격진료 이용 증가 등에 기인하는 것으로 보입니다. 예측 기간의 주요 동향으로는 기술 발전, 원격 근무, 기계 학습 통합, 인공지능, 블록체인 기술 등이 있습니다.

향후 5년간 4.3%의 성장률 전망은 지난번 예측보다 0.3% 소폭 하락한 수치입니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향에 기인합니다. 관세 부과는 영국과 이탈리아에서 수입되는 보툴리눔톡신 주사와 후두 근전도 장치에 대한 접근을 제한하고, 음성 장애 관리를 악화시키고, 이비인후과 클리닉의 비용을 증가시킬 수 있기 때문에 미국에 심각한 도전이 될 수 있습니다. 또한, 상호 관세와 무역 긴장과 제한의 증가로 인한 세계 경제와 무역에 대한 악영향으로 인해 그 영향은 더욱 광범위하게 나타날 것으로 보입니다.

경련성 발성장애 치료 시장의 성장은 연구개발 활동의 활성화가 견인할 것으로 예상됩니다. 연구개발(R&D)은 새로운 지식의 발견, 혁신적인 기술의 개발, 기존 제품, 프로세스, 서비스의 강화를 위한 체계적인 노력을 포함합니다. 이러한 활동은 기술의 발전, 정부 지원, 친환경 기술의 등장, 가상 프로토타이핑 등으로 확대되고 있습니다. 경련성 발성장애 치료 분야에서 연구개발은 과학적 이해를 증진시키고, 치료 성과를 개선하며, 경련성 발성장애 환자들의 삶의 질을 향상시키는 데 중요한 역할을 하고 있습니다. 예를 들어, 영국 통계청에 따르면 영국 정부의 R&D 투자는 2022년 10.5% 증가하여 2021년 140억 파운드에서 155억 파운드로 증가하였습니다. 이러한 증가는 연구개발 투자가 경련성 발성장애 치료 시장의 성장을 촉진하고 있음을 보여줍니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 그리고 코로나와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별·국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

제31장 기타 주요 기업과 혁신적 기업

제32장 세계의 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병

제34장 최근의 시장 동향

제35장 시장 잠재력이 높은 국가, 부문, 전략

제36장 부록

KSM
영문 목차

영문목차

Spasmodic dysphonia treatment typically involves botulinum toxin injections to relax vocal muscles and improve voice quality, accompanied by speech therapy to manage symptoms and enhance vocal control. The treatment focuses on symptom management and voice quality improvement through a combination of botulinum toxin injections, voice therapy, medications, and, in some cases, surgical interventions.

The main types of spasmodic dysphonia treatment include drugs, preventive vaccines, and oxygen therapy. Drugs for treating spasmodic dysphonia refer to medications prescribed to manage the symptoms of this neurological disorder affecting the voice muscles. Various treatments include therapy, direct microlaryngoscopy, pulse dye laser, botox injections or injection laryngoplasty, minimally invasive approaches, surgery, voice therapy, laryngeal desensitization, respiratory retraining, and others. The routes of administration include oral, parenteral, and other methods, with distribution channels such as hospital pharmacies, online pharmacies, and retail pharmacies. The treatment serves multiple end-users, including hospitals, home care, specialty clinics, and others.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The spasmodic dysphonia treatment market research report is one of a series of new reports from The Business Research Company that provides spasmodic dysphonia treatment market statistics, including spasmodic dysphonia treatment industry global market size, regional shares, competitors with a spasmodic dysphonia treatment market share, detailed spasmodic dysphonia treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the spasmodic dysphonia treatment industry. This spasmodic dysphonia treatment research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The spasmodic dysphonia treatment market size has grown steadily in recent years. It will grow from $13.79 billion in 2024 to $14.41 billion in 2025 at a compound annual growth rate (CAGR) of 4.5%. The growth in the historic period can be attributed to increased awareness and diagnosis, increased use of alternative therapies, expansion of clinical trials, the rising influence of healthcare policies, growth in public health initiatives.

The spasmodic dysphonia treatment market size is expected to see steady growth in the next few years. It will grow to $17.05 billion in 2029 at a compound annual growth rate (CAGR) of 4.3%. The growth in the forecast period can be attributed to increasing awareness about neurological disorders, rising demand for non-surgical treatments, rising prevalence of vocal disorders, growing adoption of personalized medicine approaches, and increasing use of telemedicine and remote consultations. Major trends in the forecast period include technological advancements, remote work, machine learning integration, artificial intelligence, and blockchain technology.

The forecast of 4.3% growth over the next five years reflects a modest reduction of 0.3% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. The imposition of tariffs may pose a significant challenge for the U.S. by restricting access to botulinum toxin injections and laryngeal Electromyography equipment imported from the UK and Italy, potentially worsening voice disorder management and increasing Ear, Nose, and Throat clinic costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The growth of the spasmodic dysphonia treatment market is expected to be driven by increased research and development activities. Research and development (R&D) involves systematic efforts to discover new knowledge, develop innovative technologies, or enhance existing products, processes, or services. These activities are expanding due to technological advancements, government support, the emergence of eco-friendly technologies, and virtual prototyping. In the field of spasmodic dysphonia treatment, R&D plays a critical role in advancing scientific understanding, improving therapeutic outcomes, and enhancing the quality of life for individuals affected by this challenging voice disorder. For instance, the UK government's investment in R&D rose by 10.5% in 2022, reaching £15.5 billion from £14.0 billion in 2021, according to the Office for National Statistics. This increase underscores how R&D investments are driving the growth of the spasmodic dysphonia treatment market.

Major companies in the spasmodic dysphonia treatment market are concentrating on developing effective formulations, such as botulinum toxin type A formulations, tailored to meet the specific needs of patients with this condition. Botulinum toxin type A formulations encompass various pharmaceutical preparations of this neurotoxic protein, utilized for therapeutic and cosmetic purposes to temporarily paralyze muscles or block nerve signals by inhibiting acetylcholine release at the neuromuscular junction. For example, in March 2024, Hugel Inc., a biopharmaceutical company based in South Korea, launched Letybo, a botulinum toxin approved by the FDA. Letybo features a highly purified formulation designed to minimize adverse reactions and ensure consistent treatment outcomes. Its unique molecular structure enables faster onset and prolonged effects, highlighting Hugel's commitment to stringent clinical testing and quality standards, positioning Letybo strongly in the aesthetic medicine market.

In February 2022, Healis Therapeutics LLC, a US-based biotechnology company, acquired a significant botulinum toxin patent from AbbVie Inc. This strategic acquisition enhances Healis Therapeutics' portfolio of innovative treatments and strengthens its position in the biopharmaceutical sector. AbbVie Inc., a US-based pharmaceutical company, specializes in manufacturing medications for various therapeutic areas, including spasmodic dysphonia.

Major companies operating in the spasmodic dysphonia treatment market are Johnson & Johnson Services Inc., AbbVie Inc., Mylan, Eisai Co. Ltd, GALDERMA, Ipsen Pharma, Daewoong Pharmaceutical Co. Ltd., Merz Pharma GmbH & Co. KGaA, Supernus Pharmaceuticals Inc., US WorldMeds, Candela Medical Corporation, HUGEL Inc., Evolus Inc., Revance Therapeutics Inc., Gufic Biosciences, Teijin Pharma, Suneva Medical, Healis Therapeutics, Medytox, ATGC Co. Ltd., Metabiologics Inc.

Asia-Pacific was the largest region in the spasmodic dysphonia treatment market in 2024. The regions covered in the spasmodic dysphonia treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the spasmodic dysphonia treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The spasmodic dysphonia treatment market includes revenues earned by entities by providing services such as multidisciplinary care, and medication management. The market value includes the value of related goods sold by the service provider or included within the service offering. The spasmodic dysphonia treatment market consists of sales of anticholinergic medications, alternative therapies, and speech therapy. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Spasmodic Dysphonia Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on spasmodic dysphonia treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for spasmodic dysphonia treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The spasmodic dysphonia treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Spasmodic Dysphonia Treatment Market Characteristics

3. Spasmodic Dysphonia Treatment Market Trends And Strategies

4. Spasmodic Dysphonia Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Spasmodic Dysphonia Treatment Growth Analysis And Strategic Analysis Framework

6. Spasmodic Dysphonia Treatment Market Segmentation

7. Spasmodic Dysphonia Treatment Market Regional And Country Analysis

8. Asia-Pacific Spasmodic Dysphonia Treatment Market

9. China Spasmodic Dysphonia Treatment Market

10. India Spasmodic Dysphonia Treatment Market

11. Japan Spasmodic Dysphonia Treatment Market

12. Australia Spasmodic Dysphonia Treatment Market

13. Indonesia Spasmodic Dysphonia Treatment Market

14. South Korea Spasmodic Dysphonia Treatment Market

15. Western Europe Spasmodic Dysphonia Treatment Market

16. UK Spasmodic Dysphonia Treatment Market

17. Germany Spasmodic Dysphonia Treatment Market

18. France Spasmodic Dysphonia Treatment Market

19. Italy Spasmodic Dysphonia Treatment Market

20. Spain Spasmodic Dysphonia Treatment Market

21. Eastern Europe Spasmodic Dysphonia Treatment Market

22. Russia Spasmodic Dysphonia Treatment Market

23. North America Spasmodic Dysphonia Treatment Market

24. USA Spasmodic Dysphonia Treatment Market

25. Canada Spasmodic Dysphonia Treatment Market

26. South America Spasmodic Dysphonia Treatment Market

27. Brazil Spasmodic Dysphonia Treatment Market

28. Middle East Spasmodic Dysphonia Treatment Market

29. Africa Spasmodic Dysphonia Treatment Market

30. Spasmodic Dysphonia Treatment Market Competitive Landscape And Company Profiles

31. Spasmodic Dysphonia Treatment Market Other Major And Innovative Companies

32. Global Spasmodic Dysphonia Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Spasmodic Dysphonia Treatment Market

34. Recent Developments In The Spasmodic Dysphonia Treatment Market

35. Spasmodic Dysphonia Treatment Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기